ATE460403T1 - Verbindungen und verfahren zur modulierung von fx-rezeptoren - Google Patents
Verbindungen und verfahren zur modulierung von fx-rezeptorenInfo
- Publication number
- ATE460403T1 ATE460403T1 AT07811915T AT07811915T ATE460403T1 AT E460403 T1 ATE460403 T1 AT E460403T1 AT 07811915 T AT07811915 T AT 07811915T AT 07811915 T AT07811915 T AT 07811915T AT E460403 T1 ATE460403 T1 AT E460403T1
- Authority
- AT
- Austria
- Prior art keywords
- receptors
- modulating
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80810406P | 2006-05-24 | 2006-05-24 | |
| US87000106P | 2006-12-14 | 2006-12-14 | |
| PCT/US2007/069416 WO2007140174A2 (en) | 2006-05-24 | 2007-05-22 | Compounds and methods for modulating fxr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE460403T1 true ATE460403T1 (de) | 2010-03-15 |
Family
ID=38626336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07811915T ATE460403T1 (de) | 2006-05-24 | 2007-05-22 | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8106077B2 (de) |
| EP (1) | EP2029558B1 (de) |
| JP (1) | JP5225984B2 (de) |
| AR (1) | AR061101A1 (de) |
| AT (1) | ATE460403T1 (de) |
| AU (1) | AU2007267692B2 (de) |
| BR (1) | BRPI0711875A2 (de) |
| CA (1) | CA2651373A1 (de) |
| CL (1) | CL2007001451A1 (de) |
| DE (1) | DE602007005256D1 (de) |
| EA (1) | EA014720B1 (de) |
| ES (1) | ES2340221T3 (de) |
| MX (1) | MX2008014959A (de) |
| PE (1) | PE20080259A1 (de) |
| TW (1) | TW200812982A (de) |
| WO (1) | WO2007140174A2 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1894924A1 (de) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterozyklische FXR Bindungsverbindungen |
| EP1894928A1 (de) * | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| RU2527177C2 (ru) | 2007-12-20 | 2014-08-27 | Энвиво Фармасьютикалз, Инк. | Четырехзамещенные бензолы |
| WO2009102761A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| EP2128158A1 (de) * | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen |
| BRPI0919057A2 (pt) * | 2008-09-25 | 2018-01-09 | Hoffmann La Roche | compostos de indazol ou derivados, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento ou profilaxia de enfermidades que são afetadas por moduladores de fxr, e uso dos compostos |
| EP2289883A1 (de) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4) |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US20120245176A1 (en) | 2010-09-28 | 2012-09-27 | Bristol-Myers Squibb Company | Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals |
| US8697696B2 (en) * | 2010-11-09 | 2014-04-15 | Roche Palo Alto Llc | Triazole compounds II |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| IL253437A0 (en) * | 2011-07-13 | 2017-09-28 | Gilead Sciences Inc | New compounds modulate fxr (nr1h4) activity and bind |
| EP2545964A1 (de) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| AU2013283488A1 (en) * | 2012-06-26 | 2015-01-15 | Saniona Aps | A phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| BR112016005507B1 (pt) | 2013-09-11 | 2023-02-07 | Centre National De La Recherche Scientifique (Cnrs) | Uso de um agonista do receptor farnesoide x (fxr) |
| EP3925951A1 (de) | 2014-01-24 | 2021-12-22 | SynAffix B.V. | Verfahren zur cycloaddition einer hetero(aryl)-1,3-dipol-verbindung mit einem (hetero)cycloalkyn |
| EP3006939A1 (de) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| MA41094A (fr) * | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| EP3034501A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen |
| EP3034499A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Neuartige FXR (NR1H4) modulierende Verbindungen |
| EP4035665A1 (de) | 2015-02-06 | 2022-08-03 | Intercept Pharmaceuticals, Inc. | Pharmazeutische zusammensetzungen für eine kombinationstherapie |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| TN2017000426A1 (en) | 2015-04-07 | 2019-04-12 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| SG11201810600WA (en) | 2016-06-13 | 2018-12-28 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| NZ756329A (en) | 2017-02-21 | 2025-09-26 | Genfit | Combination of a ppar agonist with a fxr agonist |
| EP4122464B1 (de) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutische kombinationen zur behandlung von lebererkrankungen |
| CN110944635A (zh) | 2017-03-30 | 2020-03-31 | 国家医疗保健研究所 | 用于减少附加体病毒的持久性和表达的方法和药物组合物 |
| US10988449B2 (en) * | 2017-04-12 | 2021-04-27 | Il Dong Pharmaceutical Co., Ltd. | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
| JP7264905B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしての多環化合物 |
| ES2944657T3 (es) | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
| EA202091084A1 (ru) | 2017-11-01 | 2020-08-13 | Бристол-Маерс Сквибб Компани | Алкеновые спироциклические соединения как модуляторы фарнезоидных x-рецепторов |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| IT201800007265A1 (it) * | 2018-07-17 | 2020-01-17 | Isossazoli come agonisti del recettore fxr | |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| BR112021011762A2 (pt) | 2019-01-15 | 2021-11-03 | Gilead Sciences Inc | Compostos para modulação de fxr (nr1h4) |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN114144185A (zh) | 2019-05-30 | 2022-03-04 | 英特塞普特医药品公司 | 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物 |
| EP3999101A1 (de) | 2019-07-18 | 2022-05-25 | ENYO Pharma | Verfahren zur verringerung von störeffekten von interferon |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| CN110878052B (zh) * | 2019-12-11 | 2021-05-07 | 山东大学 | 一种含有fxr激动剂的化合物及其制备方法和应用 |
| JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用 |
| EP4126858A1 (de) | 2020-03-26 | 2023-02-08 | Richter Gedeon Nyrt. | Dihydro-2-pyrrolo[3,4-c pyridin-derivate als gabaa a5 rezeptormodulatoren |
| CN117202905A (zh) | 2021-01-14 | 2023-12-08 | 埃尼奥制药公司 | Fxr激动剂和ifn用于治疗hbv感染的协同效果 |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CN119710733B (zh) * | 2025-02-07 | 2025-09-30 | 青岛科技大学 | 一种吲哚-3-基烷基丙二酸酯类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| ATE381542T1 (de) * | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| EP1562915A1 (de) * | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x rezeptor agonisten |
| CN1909902A (zh) * | 2003-12-22 | 2007-02-07 | 伊莱利利公司 | 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物 |
-
2007
- 2007-05-22 TW TW096118230A patent/TW200812982A/zh unknown
- 2007-05-22 AT AT07811915T patent/ATE460403T1/de not_active IP Right Cessation
- 2007-05-22 AU AU2007267692A patent/AU2007267692B2/en not_active Ceased
- 2007-05-22 JP JP2009512254A patent/JP5225984B2/ja active Active
- 2007-05-22 MX MX2008014959A patent/MX2008014959A/es active IP Right Grant
- 2007-05-22 US US12/298,769 patent/US8106077B2/en active Active
- 2007-05-22 EP EP07811915A patent/EP2029558B1/de active Active
- 2007-05-22 ES ES07811915T patent/ES2340221T3/es active Active
- 2007-05-22 CA CA002651373A patent/CA2651373A1/en not_active Abandoned
- 2007-05-22 WO PCT/US2007/069416 patent/WO2007140174A2/en not_active Ceased
- 2007-05-22 DE DE602007005256T patent/DE602007005256D1/de active Active
- 2007-05-22 EA EA200870569A patent/EA014720B1/ru not_active IP Right Cessation
- 2007-05-22 CL CL2007001451A patent/CL2007001451A1/es unknown
- 2007-05-22 BR BRPI0711875-9A patent/BRPI0711875A2/pt not_active IP Right Cessation
- 2007-05-22 AR ARP070102216A patent/AR061101A1/es not_active Application Discontinuation
- 2007-05-22 PE PE2007000629A patent/PE20080259A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2029558B1 (de) | 2010-03-10 |
| BRPI0711875A2 (pt) | 2012-01-10 |
| PE20080259A1 (es) | 2008-04-10 |
| AU2007267692B2 (en) | 2012-06-14 |
| AU2007267692A1 (en) | 2007-12-06 |
| AR061101A1 (es) | 2008-08-06 |
| US8106077B2 (en) | 2012-01-31 |
| CA2651373A1 (en) | 2007-12-06 |
| TW200812982A (en) | 2008-03-16 |
| WO2007140174A2 (en) | 2007-12-06 |
| WO2007140174A3 (en) | 2008-03-20 |
| ES2340221T3 (es) | 2010-05-31 |
| JP2009538333A (ja) | 2009-11-05 |
| MX2008014959A (es) | 2008-12-09 |
| JP5225984B2 (ja) | 2013-07-03 |
| DE602007005256D1 (de) | 2010-04-22 |
| CL2007001451A1 (es) | 2008-01-11 |
| EA014720B1 (ru) | 2011-02-28 |
| EP2029558A2 (de) | 2009-03-04 |
| EA200870569A1 (ru) | 2009-06-30 |
| US20090093524A1 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE460403T1 (de) | Verbindungen und verfahren zur modulierung von fx-rezeptoren | |
| ATE539065T1 (de) | Verbindungen und verfahren zur modulierung von fx-rezeptoren | |
| ATE540945T1 (de) | Verfahren zur modulation des gpr119-g- proteingekoppelten rezeptors und ausgewählte verbindungen | |
| EP2134176A4 (de) | Verbindungen und verfahren zur verbesserung von mhc-klasse-ii-therapien | |
| EP2142078A4 (de) | Verbesserte verfahren und vorrichtungen zur materialüberprüfung | |
| DE602005022123D1 (de) | Vorrichtung und verfahren zur beförderung von bohrklein | |
| DE602006007458D1 (de) | Verfahren und vorrichtung zur bohrlochfluidanalyse | |
| EP1934720A4 (de) | Verfahren und computerprogramm zur einrichtungskonfiguration | |
| DE602007000066D1 (de) | Verfahren und Gerät zur Verwaltung von verteilten Inhalten | |
| EP2243036A4 (de) | System und verfahren zur erfassung von aktivitäten | |
| ATE459416T1 (de) | Verfahren zur beseitigung von endokrin wirksamen verbindungen | |
| DE602007000729D1 (de) | Verfahren und Vorrichtung zur Authentifizierung | |
| DE602006006454D1 (de) | Verfahren und Vorrichtung zur Authentifizierung | |
| DE602007001241D1 (de) | Vorrichtung zur Zuweisung von Unterkanälen und entsprechendes Verfahren | |
| EP1905443A4 (de) | Flüssigkeit zur prävention von gewebeadhäsion und verfahren zur verhinderung von gewebeadhäsion | |
| EP2015023A4 (de) | Navigationseinrichtung und verfahren | |
| DE602006001379D1 (de) | Vorrichtung und Verfahren zur Erfassung von Verschiebungen | |
| DE602005024599D1 (de) | Verbindungen modulierende thrombopoietinaktivität und verfahren | |
| DE602006021341D1 (de) | Rauchgasnassentschwefelungsvorrichtung und verfahren zur rauchgasnassentschwefelung | |
| EP1997243A4 (de) | Verfahren und vorrichtung zur auswahl von kanalstreucodes | |
| EP2266633A4 (de) | Gasdekompositionsvorrichtung und verfahren zur dekomposition von gas | |
| EP2133158A4 (de) | Verfahren zur entgiftung von asbest | |
| DE602006008098D1 (de) | Verfahren und System zur Verwaltung von Datenverkehr | |
| EP2069390A4 (de) | Opsin-stabilisierende verbindungen und anwendungsverfahren dafür | |
| ATE552250T1 (de) | Verfahren zur herstellung von duloxetin und verwandten verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |